Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
FATE > SEC Filings for FATE > Form 8-K on 11-Jun-2014All Recent SEC Filings

Show all filings for FATE THERAPEUTICS INC

Form 8-K for FATE THERAPEUTICS INC


11-Jun-2014

Change in Directors or Principal Officers, Submission of Matters to a Vote


Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 6, 2014, Robert Nelsen, a director of Fate Therapeutics, Inc. (the "Company"), concluded his term on the Board of Directors of the Company and all committees thereof and did not stand for re-election at the Company's 2014 Annual Meeting of Stockholders. Mr. Nelsen previously served on the Compensation Committee. The decision of Mr. Nelsen to retire from the Board of Directors did not involve any disagreement with the Company.

Also on June 6, 2014, William Rastetter was appointed to the Compensation Committee of the Board of Directors to fill the vacancy created by Mr. Nelsen's retirement.



Item 5.07 Submission of Matters to a Vote of Security
Holders.

The following proposals were submitted to the stockholders at the 2014 Annual Meeting of Stockholders held on June 6, 2014:

(i) The election of two Class I directors, as nominated by the Board of Directors, to hold office until the 2017 Annual Meeting of Stockholders or until their successors are duly elected and qualified; and

(ii) The ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2014.

The proposals are described in detail in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 25, 2014.

The number of shares of common stock entitled to vote at the annual meeting was 20,498,428. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 17,571,224. All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.

The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

(a) Election of Class I Directors.

Director Nominee                Votes For    Votes Withheld
Robert S. Epstein, M.D., M.S.   16,883,606          124,581
John D. Mendlein, Ph.D., J.D.   16,881,506          126,681

There were 563,037 broker non-votes regarding the election of directors.

(b) Ratification of Auditors.

Stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014. The results of the voting included 17,517,381 votes for, 47,721 votes against, and 6,122 votes abstained.

There were zero broker non-votes regarding this proposal.


  Add FATE to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for FATE - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.